ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,303.27
0.12%
US Tech 100
18,062.00
-0.10%
다우존스 지수
40,003.59
0.34%
Bitcoin
66,750.61
-0.28%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Merrimack Pharmaceuticals Inc (MACK)

  7. Merrimack Pharmaceuticals Inc (MACK) 뉴스

MACK

Merrimack Pharmaceuticals (MACK)

Merrimack Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:MACK
일자시간출처헤드라인심볼기업
2024/05/1105:45Edgar (US Regulatory)Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/05/1105:43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/05/1105:30Business WireMerrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common StockNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/05/0920:45Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/05/0920:43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/05/0920:30Business WireMerrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of DissolutionNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/05/0106:15Business WireMerrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of DissolutionNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/03/2805:30Business WireMerrimack Receives $225 Million Milestone Payment from IpsenNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/03/0806:42Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/03/0806:39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/03/0806:30Business WireMerrimack Reports Full Year 2023 Financial ResultsNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/03/0806:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/03/0802:29Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/03/0606:44Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/02/2306:46Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/02/1506:20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/02/1406:26Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/02/1406:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/02/1406:18Business WireMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)NASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/02/0104:08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MACKMerrimack Pharmaceuticals Inc
2024/01/2606:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
2023/12/2906:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
2023/12/1406:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
2023/12/1206:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
2023/11/2108:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
2023/11/1707:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
2023/11/0305:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MACKMerrimack Pharmaceuticals Inc
2023/11/0305:30Business WireMerrimack Reports Third Quarter 2023 Financial ResultsNASDAQ:MACKMerrimack Pharmaceuticals Inc
2023/08/1505:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
2023/08/1005:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:MACK

최근 히스토리

EU
DMSBS
Diagnostic Medical Systems
COIN
TRUMPUSD
YUGE
EU
CRBP2
Caisse Regionale de Cred...
EU
IEPAB
LYXOR EPAB INAV
EU
1254T
1254T
AMEX
RHE-B
Regional Health Properties
COIN
GOGBP
GoChain
COIN
EECGBP
ASE
SUNLB1
Systems Sunlight
COIN
REMEUR
NASDAQ
FLFV
Feutune Light Acquisition
USOTC
ZAAG
ZA (PK)
COIN
HLCBTC
TSX
XEU
iShares MSCI Europe IMI ...
BIT
P1DDL6
BNP Paribas Issuance
AMEX
JUNT
Allianzim US Large Cap B...
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유